Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458659 | 0.78 | GABRA5 (0.45) | CNR1CNR2 | |
| SCHEMBL4678614 | 0.78 | CNR1 (0.44) | CNR1CNR2MAPT | |
| SCHEMBL5483536 | 0.76 | CNR1 (0.41) | CNR1CNR2KCNK3KCNK9LMNA | |
| SCHEMBL4681440 | 0.76 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL4680498 | 0.75 | HTT (0.48) | CNR1CNR2 | |
| SCHEMBL4677223 | 0.75 | CNR1 (0.44) | CNR1CNR2LMNA | |
| SCHEMBL4681163 | 0.75 | CNR1 (0.67) | CNR1CNR2PDE4APDE4BPDE4C | |
| SCHEMBL4676549 | 0.75 | CNR1 (0.45) | CNR1CNR2 | |
| SCHEMBL5483533 | 0.74 | CNR2 (0.46) | CNR1CNR2KCNK3KCNK9MAPT | |
| SCHEMBL5754645 | 0.74 | GABRA5 (0.43) | CNR1CNR2PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093505-A1 | 2,3-Substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1638956-A1 | 2,3-SUBSTITUTED 5,6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATORS | AstraZeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004111039-A1 | 2,3-SUBSTITUTED 5,6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093505-A1 | 2,3-Substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators | CNR2, CNR1, HTR2C | CNR1 2/4885CNR2 1/4885PDE4A 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.